ABL1 and type 1 diabetes mellitus: Intriguingly, imatinib mesylate, a selective tyrosine kinase inhibitor, targets c-Abl, antagonizes ABL–IRE1α interaction, blunts IRE1α RNase hyperactivity, reduces pancreatic β-cell apoptosis, and reverses type 1 diabetes (T1D) in the non-obese diabetic (NOD) mouse model [331].